Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
US FDA Flags Safety Ahead Of Meeting
Executive Summary
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
You may also be interested in...
GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.
Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.